Pharmacotherapy of Glaucoma

Journal of Ocular Pharmacology and Therapeutics

Volumn 31, Issue 2, 2015, Pages 63-77

  Schmidl, Doreen ^a   Schmetterer, Leopold ^a,b   Garhöfer, Gerhard ^a   Popa Cherecheanu, Alina ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Christian Doppler Laboratory for Innovative Optical Imaging and its Translation to Medicine   (Austria)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; OSMOTIC AGENT; PROSTAGLANDIN DERIVATIVE;

AQUEOUS HUMOR FORMATION; AQUEOUS HUMOR OUTFLOW; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SYSTEMIC THERAPY; TOPICAL TREATMENT; TRABECULAR MESHWORK; ANIMAL; CLINICAL TRIAL; DRUG EFFECTS; MULTICENTER STUDY;

ANIMALS; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE;

EID: 84934282236     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2014.0067     Document Type: Review

References (197)

1. Cherecheanu, A.P., Garhofer, G., Schmidl, D., Werkmeister, R., and Schmetterer, L. Ocular perfusion pressure and ocular blood flow in glaucoma. Curr. Opin. Pharmacol. 13:36-42, 2013.
2. Coleman, A.L., and Miglior, S. Risk factors for glaucoma onset and progression. Surv. Ophthalmol. 53 Suppl 1:S3-S10, 2008.
3. Gabelt, B.T., and Kaufman, P.L. Aqueous humor hydrodynamics. In: Hart, W.M., ed. Adler's Physiology of the Eye. 9th ed. St. Louis: MO: Mosby; 2003.
4. Chowdhury, U.R., Madden, B.J., Charlesworth, M.C., and Fautsch, M.P. Proteome analysis of human aqueous humor. Invest. Ophthalmol. Vis. Sci. 51:4921-4931, 2010.
5. Goel, M., Picciani, R.G., Lee, R.K., and Bhattacharya, S.K. Aqueous humor dynamics: a review. Open Ophthalmol. J. 4:52-59, 2010.
6. Civan, M.M., and Macknight, A.D.C. The ins and outs of aqueous humour secretion. Exp. Eye Res. 78:625-631, 2004.
7. Schey, K.L., Wang, Z., Wenke, J.L., and Qi, Y. Aquaporins in the eye: expression, function, and roles in ocular disease. BBA-Gen. Subj. 1840:1513-1523, 2014.
8. Heys, J.J., and Barocas, V.H. A boussinesq model of natural convection in the human eye and the formation of Krukenberg's spindle. Ann. Biomed. Eng. 30:392-401, 2002.
9. Tamm, E.R. The trabecular meshwork outflow pathways: structural and functional aspects. Exp. Eye Res. 88:648-655, 2009.
10. Johnson, M. 'What controls aqueous humour outflow resistance?'. Exp. Eye Res. 82:545-557, 2006.
11. Bill, A. Some aspects of aqueous humour drainage. Eye. 7:14-19, 1993.
12. Stamer, W.D., and Acott, T.S. Current understanding of conventional outflow dysfunction in glaucoma. Curr. Opin. Ophthalmol. 23:135-143, 2012.
13. Ramos, R.F., Hoying, J.B., Witte, M.H., and Daniel Stamer, W. Schlemm's canal endothelia, lymphatic, or blood vasculature? J. Glaucoma. 16:391-405, 2007.
14. Alm, A., and Nilsson, S.F.E. Uveoscleral outflow-a review. Exp. Eye Res. 88:760-768, 2009.
15. Nilsson, S.F.E. The uveoscleral outflow routes. Eye. 11:149-154, 1997.
16. Yucel, Y.H., Johnston, M.G., Ly, T., et al. Identification of lymphatics in the ciliary body of the human eye: a novel ''uveolymphatic'' outflow pathway. Exp. Eye Res. 89:810-819, 2009.
17. Kim, M., Johnston, M.G., Gupta, N., Moore, S., and Yucel, Y.H. A model to measure lymphatic drainage from the eye. Exp. Eye Res. 93:586-591, 2011.
18. Tam, A.L., Gupta, N., Zhang, Z., and Yucel, Y.H. Latanoprost stimulates ocular lymphatic drainage: an in vivo nanotracer study. Transl. Vis. Sci. Technol. 2:3, 2013.
19. Truong, T.N., Li, H., Hong, Y.K., and Chen, L. Novel characterization and live imaging of Schlemm's canal expressing Prox-1. PLoS One. 9:e98245, 2014.
20. Vass, C., Hirn, C., Sycha, T., Findl, O., Bauer, P., and Schmetterer, L. Medical interventions for primary open angle glaucoma and ocular hypertension. Cochrane Database Syst. Rev. CD003167, 2007.
21. Alvarado, J., Murphy, C., and Juster, R. Trabecular meshwork cellularity in primary open-angle glaucoma and nonglaucomatous normals. Ophthalmology. 91:564-579, 1984.
22. Rohen, J.W., Lutjen-Drecoll, E., Flugel, C., Meyer, M., and Grierson, I. Ultrastructure of the trabecular meshwork in untreated cases of primary open-angle glaucoma (POAG). Exp. Eye Res. 56:683-692, 1993.
23. Gottanka, J., Johnson, D.H., Martus, P., and Lutjen-Drecoll, E. Severity of optic nerve damage in eyes with POAG is correlated with changes in the trabecular meshwork. J. Glaucoma. 6:123-132, 1997.
24. Fuchshofer, R., and Tamm, E.R. The role of TGF-beta in the pathogenesis of primary open-angle glaucoma. Cell. Tissue Res. 347:279-290, 2012.
25. Babizhayev, M.A. Biomarkers and special features of oxidative stress in the anterior segment of the eye linked to lens cataract and the trabecular meshwork injury in primary open-angle glaucoma: challenges of dual combination therapy with N-acetylcarnosine lubricant eye drops and oral formulation of nonhydrolyzed carnosine. Fundam. Clin. Pharmacol. 26:86-117, 2012.
26. McDonnell, F., O'Brien, C., and Wallace, D. The role of epigenetics in the fibrotic processes associated with glaucoma. J. Ophthalmol. 2014:750459, 2014.
27. Flammer, J., Orgul, S., Costa, V.P., et al. The impact of ocular blood flow in glaucoma. Prog. Retin. Eye Res. 21:359-393, 2002.
28. Sehi, M., Goharian, I., Konduru, R., et al. Retinal blood flow in glaucomatous eyes with single-hemifield damage. Ophthalmology. 121:750-758, 2014.
29. Resch, H., Schmidl, D., Hommer, A., et al. Correlation of optic disc morphology and ocular perfusion parameters in patients with primary open angle glaucoma. Acta Ophthalmol. 89:e544-S549, 2011.
30. Portmann, N., Gugleta, K., Kochkorov, A., Polunina, A., Flammer, J., and Orgul, S. Choroidal blood flow response to isometric exercise in glaucoma patients and patients with ocular hypertension. Invest. Ophthalmol. Vis. Sci. 52:7068-7073, 2011.
31. Feke, G.T., and Pasquale, L.R. Retinal blood flow response to posture change in glaucoma patients compared with healthy subjects. Ophthalmology. 115:246-252, 2008.
32. Fuchsjager-Mayrl, G., Wally, B., Georgopoulos, M., et al. Ocular blood flow and systemic blood pressure in patients with primary open-angle glaucoma and ocular hypertension. Invest. Ophthalmol. Vis. Sci. 45:834-839, 2004.
33. Schmidl, D., Garhofer, G., and Schmetterer, L. The complex interaction between ocular perfusion pressure and ocular blood flow-relevance for glaucoma. Exp. Eye Res. 93:141-155, 2011.
34. Leske, M.C., Heijl, A., Hyman, L., Bengtsson, B., Dong, L., and Yang, Z. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 114:1965-1972, 2007.
35. Leske, M.C., Wu, S.Y., Hennis, A., Honkanen, R., and Nemesure, B. Risk factors for incident open-angle glaucoma: the Barbados Eye Studies. Ophthalmology. 115:85-93, 2008.
36. Bonomi, L., Marchini, G., Marraffa, M., Bernardi, P., Morbio, R., and Varotto, A. Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. Ophthalmology. 107:1287-1293, 2000.
37. Costa, V.P., Harris, A., Anderson, D., et al. Ocular perfusion pressure in glaucoma. Acta Ophthalmol. 92:e252-e266, 2014.
38. Caprioli, J., and Coleman, A.L. Blood pressure, perfusion pressure, and glaucoma. Am. J. Ophthalmol. 149:704-712, 2010.
39. He, Z., Vingrys, A.J., Armitage, J.A., and Bui, B.V. The role of blood pressure in glaucoma. Clin. Exp. Optom. 94:133-149, 2011.
40. Leske, M.C. Ocular perfusion pressure and glaucoma: clinical trial and epidemiologic findings. Curr. Opin. Ophthalmol. 20:73-78, 2009.
41. Philipp, M., Brede, M., and Hein, L. Physiological significance of alpha(2)-adrenergic receptor subtype diversity: one receptor is not enough. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283:R287-R295, 2002.
42. Toris, C.B. Pharmacotherapies for glaucoma. Curr. Mol. Med. 10:824-840, 2010.
43. Arthur, S., and Cantor, L.B. Update on the role of alphaagonists in glaucoma management. Exp. Eye Res. 93:271-283, 2011.
44. Toris, C.B., Camras, C.B., and Yablonski, M.E. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am. J. Ophthalmol. 128:8-14, 1999.
45. European Glaucoma Society. Terminology and guidelines for glaucoma. III ed. Savona: Editrice DOGMA; 2008.
46. Kalapesi, F.B., Coroneo, M.T., and Hill, M.A. Human ganglion cells express the alpha-2 adrenergic receptor: relevance to neuroprotection. Br. J. Ophthalmol. 89:758-763, 2005.
47. Vidal-Sanz, M., Lafuente, M.P., Mayor-Torroglosa, S., Aguilera, M.E., Miralles de Imperial, J., and Villegas-Perez, M.P. Brimonidine's neuroprotective effects against transient ischaemia-induced retinal ganglion cell death. Eur. J. Ophthalmol. 11 Suppl 2:S36-S40, 2001.
48. Lafuente López-Herrera, M., amp, x., et al. Transient ischemia of the retina results in altered retrograde axoplasmic transport: neuroprotection with brimonidine. Exp. Neurol. 178:243-258, 2002.
49. Hernandez, M., Urcola, J.H., and Vecino, E. Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments. Exp. Eye Res. 86:798-806, 2008.
50. Dong, C.-J., Guo, Y., Agey, P., Wheeler, L., and Hare, W.A. a2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest. Ophthalmol. Vis. Sci. 49:4515-4522, 2008.
51. Krupin, T., Liebmann, J.M., Greenfield, D.S., Ritch, R., and Gardiner, S. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am. J. Ophthalmol. 151:671-681, 2011.
52. Kersey, T., Clement, C.I., Bloom, P., and Cordeiro, M.F. New trends in glaucoma risk, diagnosis & management. Indian J. Med. Res. 137:659-668, 2013.
53. Grieshaber, M.C., and Flammer, J. Is the medication used to achieve the target intraocular pressure in glaucoma therapy of relevance?-an exemplary analysis on the basis of two beta-blockers. Prog. Retin. Eye Res. 29:79-93, 2010.
54. Pfeiffer, N., Lamparter, J., Gericke, A., Grus, F.H., Hoffmann, E.M., and Wahl, J. Neuroprotection of medical IOP-lowering therapy. Cell. Tissue Res. 353:245-251, 2013.
55. Lama, P.J. Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment. Am. J. Ophthalmol. 134:749-760, 2002.
56. Wood, J.P.M., Schmidt, K.G., Melena, J., Chidlow, G., Allmeier, H., and Osborne, N.N. The b-adrenoceptor antagonists metipranolol and timolol are retinal neuroprotectants: comparison with betaxolol. Exp. Eye Res. 76:505-516, 2003.
57. Seki, M., Tanaka, T., Matsuda, H., et al. Topically administered timolol and dorzolamide reduce intraocular pressure and protect retinal ganglion cells in a rat experimental glaucoma model. Br. J. Ophthalmol. 89:504-507, 2005.
58. Osborne, N.N., Wood, J.P., and Chidlow, G. Invited review: neuroprotective properties of certain beta-adrenoceptor antagonists used for the treatment of glaucoma. J. Ocul. Pharmacol. Ther. 21:175-181, 2005.
59. Sambhara, D., and Aref, A.A. Glaucoma management: relative value and place in therapy of available drug treatments. Ther. Adv. Chronic. Dis. 5:30-43, 2014.
60. Kiss, B., Dallinger, S., Findl, O., Rainer, G., Eichler, H.G., and Schmetterer, L. Acetazolamide-induced cerebral and ocular vasodilation in humans is independent of nitric oxide. Am. J. Physiol. 276:R1661-R1667, 1999.
61. Dahl, A., Russell, D., Nyberg-Hansen, R., Rootwelt, K., and Mowinckel, P. Simultaneous assessment of vasoreactivity using transcranial Doppler ultrasound and cerebral blood flow in healthy subjects. J. Cereb. Blood Flow Metab. 14:974-981, 1994.
62. Dallinger, S., Bobr, B., Findl, O., Eichler, H.G., and Schmetterer, L. Effects of acetazolamide on choroidal blood flow. Stroke. 29:997-1001, 1998.
63. Barnes, G.E., Li, B., Dean, T., and Chandler, M.L. Increased optic nerve head blood flow after 1 week of twice daily topical brinzolamide treatment in Dutch-belted rabbits. Surv. Ophthalmol. 44 Suppl 2:S131-S140, 2000.
64. Siesky, B., Harris, A., Cantor, L.B., et al. A comparative study of the effects of brinzolamide and dorzolamide on retinal oxygen saturation and ocular microcirculation in patients with primary open-angle glaucoma. Br. J. Ophthalmol. 92:500-504, 2008.
65. Iester, M., Altieri, M., Michelson, G., Vittone, P., Traverso, C.E., and Calabria, G. Retinal peripapillary blood flow before and after topical brinzolamide. Ophthalmologica. 218:390-396, 2004.
66. Rolle, T., Tofani, F., Brogliatti, B., and Grignolo, F.M. The effects of dorzolamide 2% and dorzolamide/timolol fixed combination on retinal and optic nerve head blood flow in primary open-angle glaucoma patients. Eye (Lond). 22:1172-1179, 2008.
67. Fuchsjager-Mayrl, G., Wally, B., Rainer, G., et al. Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension. Br. J. Ophthalmol. 89:1293-1297, 2005.
68. Nagel, E., Vilser, W., and Lanzl, I. Dorzolamide influences the autoregulation of major retinal vessels caused by artificial intraocular pressure elevation in patients with POAG: a clinical study. Curr. Eye. Res. 30:129-137, 2005.
69. Fuchsjager-Mayrl, G., Georgopoulos, M., Hommer, A., et al. Effect of dorzolamide and timolol on ocular pressure: blood flow relationship in patients with primary open-angle glaucoma and ocular hypertension. Invest. Ophthalmol. Vis. Sci. 51:1289-1296, 2010.
70. Schallenberg, M., Prokosch, V., and Thanos, S. Regulation of retinal proteome by topical antiglaucomatous eye drops in an inherited glaucoma rat model. PLoS One. 7:e33593, 2012.
71. Zanon-Moreno, V., Garcia-Medina, J.J., Gallego-Pinazo, R., Vinuesa-Silva, I., Moreno-Nadal, M.A., and Pinazo-Duran, M.D. Antioxidant status modifications by topical administration of dorzolamide in primary open-angle glaucoma. Eur. J. Ophthalmol. 19:565-571, 2009.
72. Saccà, S., La Maestra, S., Micale, R.T., et al. Ability of dorzolamide hydrochloride and timolol maleate to target mitochondria in glaucoma therapy. Arch. Ophthalmol. 129:48-55, 2011.
73. Martinez, A., and Sanchez-Salorio, M. Predictors for visual field progression and the effects of treatment with dorzolamide 2% or brinzolamide 1% each added to timolol 0.5% in primary open-angle glaucoma. Acta Ophthalmol. 88:541-552, 2010.
74. Miglior, S., Zeyen, T., Pfeiffer, N., Cunha-Vaz, J., Torri, V., and Adamsons, I. Results of the European Glaucoma Prevention Study. Ophthalmology. 112:366-375, 2005.
75. Quigley H.A. European Glaucoma Prevention Study. Ophthalmology. 2005;112:1642-1643; author reply 1643-1645.
76. Zhou, W., Zhu, X., Zhu, L., et al. Neuroprotection of muscarinic receptor agonist pilocarpine against glutamateinduced apoptosis in retinal neurons. Cell. Mol. Neurobiol. 28:263-275, 2008.
77. Tan, P.P., Yuan, H.H., Zhu, X., et al. Activation of muscarinic receptors protects against retinal neurons damage and optic nerve degeneration in vitro and in vivo models. CNS Neurosci. Ther. 20:227-236, 2014.
78. Espada, S., Rojo, A.I., Salinas, M., and Cuadrado, A. The muscarinic M1 receptor activates Nrf2 through a signaling cascade that involves protein kinase C and inhibition of GSK-3beta: connecting neurotransmission with neuroprotection. J. Neurochem. 110:1107-1119, 2009.
79. Shaikh, M.H., and Mars, J.S. The acute effect of pilocarpine on pulsatile ocular blood flow in ocular hypertension. Eye (Lond). 15:63-66, 2001.
80. Claridge, K.G. The effect of topical pilocarpine on pulsatile ocular blood flow. Eye (Lond). 7:507-510, 1993.
81. Schmetterer, L., Strenn, K., Findl, O., et al. Effects of antiglaucoma drugs on ocular hemodynamics in healthy volunteers. Clin. Pharmacol. Ther. 61:583-595, 1997.
82. Weinreb, R.N., Toris, C.B., Gabelt, B.A.T., Lindsey, J.D., and Kaufman, P.L. Effects of prostaglandins on the aqueous humor outflow pathways. Surv. Ophthalmol. 47 Suppl 1:S53-S64, 2002.
83. Yamagishi, R., Aihara, M., and Araie, M. Neuroprotective effects of prostaglandin analogues on retinal ganglion cell death independent of intraocular pressure reduction. Exp. Eye Res. 93:265-270, 2011.
84. Kanamori, A., Naka, M., Fukuda, M., Nakamura, M., and Negi, A. Latanoprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo. Exp. Eye Res. 88:535-541, 2009.
85. Nakanishi, Y., Nakamura, M., Mukuno, H., Kanamori, A., Seigel, G.M., and Negi, A. Latanoprost rescues retinal neuro-glial cells from apoptosis by inhibiting caspase-3, which is mediated by p44/p42 mitogen-activated protein kinase. Exp. Eye Res. 83:1108-1117, 2006.
86. Takano, N., Tsuruma, K., Ohno, Y., Shimazawa, M., and Hara, H. Bimatoprost protects retinal neuronal damage via Akt pathway. Eur. J. Pharmacol. 702:56-61, 2013.
87. Cuppoletti, J., Malinowska, D.H., Tewari, K.P., Chakrabarti, J., and Ueno, R. Cellular and molecular effects of unoprostone as a BK channel activator. BBA-Biomembrans. 1768:1083-1092, 2007.
88. Akaishi, T., Kurashima, H., Odani-Kawabata, N., Ishida, N., and Nakamura, M. Effects of repeated administrations of tafluprost, latanoprost, and travoprost on optic nerve head blood flow in conscious normal rabbits. J. Ocul. Pharmacol. Ther. 26:181-186, 2010.
89. Kimura, I., Shinoda, K., Tanino, T., Ohtake, Y., and Mashima, Y. Effect of topical unoprostone isopropyl on optic nerve head circulation in controls and in normaltension glaucoma patients. Jpn. J. Ophthalmol. 49:287-293, 2005.
90. Ishii, K., Tomidokoro, A., Nagahara, M., et al. Effects of topical latanoprost on optic nerve head circulation in rabbits, monkeys, and humans. Invest. Ophthalmol. Vis. Sci. 42:2957-2963, 2001.
91. Izumi, N., Nagaoka, T., Sato, E., et al. Short-term effects of topical tafluprost on retinal blood flow in cats. J. Ocul. Pharmacol. Ther. 24:521-526, 2008.
92. Boltz, A., Schmidl, D., Weigert, G., et al. Effect of latanoprost on choroidal blood flow regulation in healthy subjects. Invest. Ophthalmol. Vis. Sci. 52:4410-4415, 2011.
93. Garway-Heath, D.F., Lascaratos, G., Bunce, C., Crabb, D.P., Russell, R.A., and Shah, A. The United Kingdom Glaucoma Treatment Study: a multicenter, randomized, placebo-controlled clinical trial: design and methodology. Ophthalmology. 120:68-76, 2013.
94. Garway-Heath, D., Lascaratos, G., Bunce, C., et al. The United Kingdom Glaucoma Treatment Study (UKGTS): baseline characteristics and main outcomes. Invest. Ophthalmol. Vis. Sci. 54:2619-, 2013.
95. Sena, D.F., and Lindsley, K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst. Rev. 2:CD006539, 2013.
96. Schmetterer, L. Are all glaucoma drugs equally effective? Acta Ophthalmol. 88:503, 2010.
97. Kaur, I.P., Smitha, R., Aggarwal, D., and Kapil, M. Acetazolamide: future perspective in topical glaucoma therapeutics. Int. J. Pharm. 248:1-14, 2002.
98. Zinkernagel, M.S., and Ebneter, A. Acetazolamide influences ocular pulse amplitude. J. Ocul. Pharmacol. Ther. 25:141-144, 2009.
99. Haustein, M., Spoerl, E., and Boehm, A.G. The effect of acetazolamide on different ocular vascular beds. Graefes Arch. Clin. Exp. Ophthalmol. 251:1389-1398, 2013.
100. Rassam, S.M., Patel, V., and Kohner, E.M. The effect of acetazolamide on the retinal circulation. Eye (Lond). 7:697-702, 1993.
101. Flammer, J., Pache, M., and Resink, T. Vasospasm, its role in the pathogenesis of diseases with particular reference to the eye. Prog. Retin. Eye Res. 20:319-349, 2001.
102. Mayama, C., and Araie, M. Effects of antiglaucoma drugs on blood flow of optic nerve heads and related structures. Jpn. J. Ophthalmol. 57:133-149, 2013.
103. Muskens, R.P., de Voogd, S., Wolfs, R.C., et al. Systemic antihypertensive medication and incident open-angle glaucoma. Ophthalmology. 114:2221-2226, 2007.
104. Khawaja, A.P., Chan, M.P., Broadway, D.C., et al. Systemic medication and intraocular pressure in a British population: the EPIC-Norfolk Eye Study. Ophthalmology. 121:1501-1507, 2014.
105. McGwin, G., Jr., McNeal, S., Owsley, C., Girkin, C., Epstein, D., and Lee, P.P. Statins and other cholesterollowering medications and the presence of glaucoma. Arch. Ophthalmol. 122:822-826, 2004.
106. Budenz, D.L. A clinician's guide to the assessment and management of nonadherence in glaucoma. Ophthalmology. 116:S43-S47, 2009.
107. Schwartz, G.F., and Quigley, H.A. Adherence and persistence with glaucoma therapy. Surv. Ophthalmol. 53 Suppl 1:S57-S68, 2008.
108. Hommer, A. [Combination therapy in the medical treatment of glaucoma]. Klin. Monbl. Augenheilkd. 230:133-140, 2013.
109. Hollo, G., Topouzis, F., and Fechtner, R.D. Fixedcombination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert. Opin. Pharmacother. 15:1737-1747, 2014.
110. Nguyen, Q.H. Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus. Patient Prefer. Adherence. 8:853-864, 2014.
111. Baudouin, C., Labbe, A., Liang, H., Pauly, A., and Brignole-Baudouin, F. Preservatives in eyedrops: the good, the bad and the ugly. Prog. Retin. Eye Res. 29:312-334, 2010.
112. Knight, O.J., and Lawrence, S.D. Sustained drug delivery in glaucoma. Curr. Opin. Ophthalmol. 25:112-117, 2014.
113. Buys, E.S., Potter, L.R., Pasquale, L.R., and Ksander, B.R. Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma. Front Mol. Neurosci. 7:38, 2014.
114. Cavet, M.E., Vittitow, J.L., Impagnatiello, F., Ongini, E., and Bastia, E. Nitric oxide (NO): an emerging target for the treatment of glaucoma. Invest. Ophthalmol. Vis. Sci. 55:5005-5015, 2014.
115. Schmetterer, L., and Polak, K. Role of nitric oxide in the control of ocular blood flow. Prog. Retin. Eye Res. 20:823-847, 2001.
116. Borghi, V., Bastia, E., Guzzetta, M., et al. A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma. J. Ocul. Pharmacol. Ther. 26:125-132, 2010.
117. Impagnatiello, F., Borghi, V., Gale, D.C., et al. A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs. Exp. Eye Res. 93:243-249, 2011.
118. Krauss, A.H., Impagnatiello, F., Toris, C.B., et al. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2alpha agonist, in preclinical models. Exp. Eye Res. 93:250-255, 2011. http://bmctoday .net/glaucomatoday/2012/04/article.asp?f=glaucomacandidate-bol303259x-meets-primary-endpoint-in-phase-2b-study
119. Glaucoma Candidate BOL-303259-X Meets Primary Endpoint in Phase 2b Study. Glaucoma Today: Bryn Mawr Communications LLC; 2012.
120. Sparatore, A., Santus, G., Giustarini, D., Rossi, R., and Del Soldato, P. Therapeutic potential of new hydrogen sulfide-releasing hybrids. Expert. Rev. Clin. Pharmacol. 4:109-121, 2011.
121. Osborne, N.N., Ji, D., Majid, A.S., Del Soldata, P., and Sparatore, A. Glutamate oxidative injury to RGC-5 cells in culture is necrostatin sensitive and blunted by a hydrogen sulfide (H2S)-releasing derivative of aspirin (ACS14). Neurochem. Int. 60:365-378, 2012.
122. Inoue, T., and Tanihara, H. Rho-associated kinase inhibitors: a novel glaucoma therapy. Prog. Retin. Eye Res. 37:1-12, 2013.
123. Williams, R.D., Novack, G.D., van Haarlem, T., and Kopczynski, C. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am. J. Ophthalmol. 152:834-841 e831, 2011.
124. Zhang, K., Zhang, L., and Weinreb, R.N. Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat. Rev. Drug Discov. 11:541-559, 2012.
125. Peterson, J.A., Tian, B., McLaren, J.W., Hubbard, W.C., Geiger, B., and Kaufman, P.L. Latrunculins' effects on intraocular pressure, aqueous humor flow, and corneal endothelium. Invest. Ophthalmol. Vis. Sci. 41:1749-1758, 2000.
126. Peterson, J.A., Tian, B., Geiger, B., and Kaufman, P.L. Effect of latrunculin-B on outflow facility in monkeys. Exp. Eye Res. 70:307-313, 2000.
127. Tian, B., Gabelt, B.T., Crosson, C.E., and Kaufman, P.L. Effects of adenosine agonists on intraocular pressure and aqueous humor dynamics in cynomolgus monkeys. Exp. Eye Res. 64:979-989, 1997.
128. Polska, E., Ehrlich, P., Luksch, A., Fuchsjager-Mayrl, G., and Schmetterer, L. Effects of adenosine on intraocular pressure, optic nerve head blood flow, and choroidal blood flow in healthy humans. Invest. Ophthalmol. Vis. Sci. 44:3110-3114, 2003.
129. Osborne, N.N. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol. 87:450-454, 2009.
130. Quigley, H.A. Clinical trials for glaucoma neuroprotection are not impossible. Curr. Opin. Ophthalmol. 23:144-154, 2012.
131. Zhu, H., Russell, R.A., Saunders, L.J., Ceccon, S., Garway-Heath, D.F., and Crabb, D.P. Detecting changes in retinal function: Analysis with Non-Stationary Weibull Error Regression and Spatial enhancement (ANSWERS). PLoS One. 9:e85654, 2014.
132. Harwerth, R.S., Wheat, J.L., Fredette, M.J., and Anderson, D.R. Linking structure and function in glaucoma. Prog. Retin. Eye Res. 29:249-271, 2010.
133. Malik, R., Swanson, W.H., and Garway-Heath, D.F. 'Structure-function relationship' in glaucoma: past thinking and current concepts. Clin. Exp. Ophthalmol. 40:369-380, 2012.
134. Riva, C.E., Geiser, M., and Petrig, B.L. Ocular blood flow assessment using continuous laser Doppler flowmetry. Acta Ophthalmol. 88:622-629, 2010.
135. Sugiyama, T., Araie, M., Riva, C.E., Schmetterer, L., and Orgul, S. Use of laser speckle flowgraphy in ocular blood flow research. Acta Ophthalmol. 88:723-729, 2010.
136. Stalmans, I., Vandewalle, E., Anderson, D.R., et al. Use of colour Doppler imaging in ocular blood flow research. Acta Ophthalmol. 89:e609-S630, 2011.
137. Grover, D.S., and Budenz, D.L. Ocular perfusion pressure and glaucoma. Int. Ophthalmol. Clin. 51:19-25, 2011.
138. Mozaffarieh, M., and Flammer, J. Is there more to glaucoma treatment than lowering IOP? Surv. Ophthalmol. 52 Suppl 2:S174-S179, 2007.
139. Kiel, J.W. Modulation of choroidal autoregulation in the rabbit. Exp. Eye Res. 69:413-429, 1999.
140. Kiel, J.W., and van Heuven, W.A. Ocular perfusion pressure and choroidal blood flow in the rabbit. Invest. Ophthalmol. Vis. Sci. 36:579-585, 1995.
141. Luksch, A., Polska, E., Imhof, A., et al. Role of NO in choroidal blood flow regulation during isometric exercise in healthy humans. Invest. Ophthalmol. Vis. Sci. 44:734-739, 2003.
142. Fuchsjager-Mayrl, G., Luksch, A., Malec, M., Polska, E., Wolzt, M., and Schmetterer, L. Role of endothelin-1 in choroidal blood flow regulation during isometric exercise in healthy humans. Invest. Ophthalmol. Vis. Sci. 44:728-733, 2003.
143. Polska, E., Simader, C., Weigert, G., et al. Regulation of choroidal blood flow during combined changes in intraocular pressure and arterial blood pressure. Invest. Ophthalmol. Vis. Sci. 48:3768-3774, 2007.
144. Schmidl, D., Boltz, A., Kaya, S., et al. Role of nitric oxide in optic nerve head blood flow regulation during an experimental increase in intraocular pressure in healthy humans. Exp. Eye Res. 116:247-253, 2013.
145. Schmidl, D., Boltz, A., Kaya, S., et al. Role of nitric oxide in optic nerve head blood flow regulation during isometric exercise in healthy humans. Invest. Ophthalmol. Vis. Sci. 54:1964-1970, 2013.
146. Boltz A., Schmidl, D., Werkmeister, R.M., et al. Role of endothelin-A receptors in optic nerve head red cell flux regulation during isometric exercise in healthy humans. Am. J. Physiol. Heart Circ. Physiol. 2013;304:H170-H174.
147. Boltz, A., Schmidl, D., Werkmeister, R.M., et al. Regulation of optic nerve head blood flow during combined changes in intraocular pressure and arterial blood pressure. J. Cereb. Blood Flow Metab. 33:1850-1856, 2013.
148. Boltz, A., Told, R., Napora, K.J., et al. Optic nerve head blood flow autoregulation during changes in arterial blood pressure in healthy young subjects. PLoS One. 8:e82351, 2013.
149. Almasieh, M., MacIntyre, J.N., Pouliot, M., et al. Acetylcholinesterase inhibition promotes retinal vasoprotection and increases ocular blood flow in experimental glaucoma. Invest. Ophthalmol. Vis. Sci. 54:3171-3183, 2013.
150. Schwartz, M., Belkin, M., Yoles, E., and Solomon, A. Potential treatment modalities for glaucomatous neuropathy: neuroprotection and neuroregeneration. J. Glaucoma. 5:427-432, 1996.
151. Levin, L.A. Direct and indirect approaches to neuroprotective therapy of glaucomatous optic neuropathy. Surv. Ophthalmol. 43 Suppl 1:S98-S101, 1999.
152. Osborne, N.N., Chidlow, G., Nash, M.S., and Wood, J.P. The potential of neuroprotection in glaucoma treatment. Curr. Opin. Ophthalmol. 10:82-92, 1999.
153. Baltmr, A., Duggan, J., Nizari, S., Salt, T.E., and Cordeiro, M.F. Neuroprotection in glaucoma-Is there a future role? Exp. Eye Res. 91:554-566, 2010.
154. Danesh-Meyer, H.V. Neuroprotection in glaucoma: recent and future directions. Curr. Opin. Ophthalmol. 22:78-86, 2011.
155. Kitsos, E.B.G. Neuroprotective Agents in Glaucoma. In: Kubena, T. ed. The Mystery of Glaucoma. INTECH; 2011. http://de.scribd.com/doc/115450822/The-Mystery-of-Glaucoma, accessed on January 5, 2015.
156. Almasieh, M., Wilson, A.M., Morquette, B., Cueva Vargas, J.L., and Di Polo, A. The molecular basis of retinal ganglion cell death in glaucoma. Prog. Retin. Eye Res. 31:152-181, 2012.
157. Tsai, J.C. Canadian Journal of Ophthalmology Lecture: translational research advances in glaucoma neuroprotection. Can. J. Ophthalmol. 48:141-145, 2013.
158. Garcia-Valenzuela, E., Shareef, S., Walsh, J., and Sharma, S.C. Programmed cell death of retinal ganglion cells during experimental glaucoma. Exp. Eye Res. 61:33-44, 1995.
159. Kerrigan, L.A., Zack, D.J., Quigley, H.A., Smith, S.D., and Pease, M.E. TUNEL-positive ganglion cells in human primary open-angle glaucoma. Arch. Ophthalmol. 115:1031-1035, 1997.
160. Guerin, M.B., McKernan, D.P., O'Brien, C.J., and Cotter, T.G. Retinal ganglion cells: dying to survive. Int. J. Dev. Biol. 50:665-674, 2006.
161. Kisiswa, L., Dervan, A.G., Albon, J., Morgan, J.E., and Wride, M.A. Retinal ganglion cell death postponed: giving apoptosis a break? Ophthalmic. Res. 43:61-78, 2010.
162. Lau, A., and Tymianski, M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch. 460:525-542, 2010.
163. Zlokovic, B.V. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat. Rev. Neurosci. 12:723-738, 2011.
164. Pease, M.E., McKinnon, S.J., Quigley, H.A., Kerrigan-Baumrind, L.A., and Zack, D.J. Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Invest. Ophthalmol. Vis. Sci. 41:764-774, 2000.
165. Di Polo, A., Aigner, L.J., Dunn, R.J., Bray, G.M., and Aguayo, A.J. Prolonged delivery of brain-derived neurotrophic factor by adenovirus-infected Muller cells temporarily rescues injured retinal ganglion cells. Proc. Natl. Acad. Sci. U S A. 95:3978-3983, 1998.
166. Klocker, N., Kermer, P., Weishaupt, J.H., Labes, M., Ankerhold, R., and Bahr, M. Brain-derived neurotrophic factor-mediated neuroprotection of adult rat retinal ganglion cells in vivo does not exclusively depend on phosphatidyl-inositol-3'-kinase/protein kinase B signaling. J. Neurosci. 20:6962-6967, 2000.
167. Parrilla-Reverter, G., Agudo, M., Sobrado-Calvo, P., Salinas-Navarro, M., Villegas-Perez, M.P., and Vidal-Sanz, M. Effects of different neurotrophic factors on the survival of retinal ganglion cells after a complete intraorbital nerve crush injury: a quantitative in vivo study. Exp. Eye Res. 89:32-41, 2009.
168. Sivak, J.M. The aging eye: common degenerative mechanisms between the Alzheimer's brain and retinal disease. Invest. Ophthalmol. Vis. Sci. 54:871-880, 2013.
169. Goldblum, D., Kipfer-Kauer, A., Sarra, G.M., Wolf, S., and Frueh, B.E. Distribution of amyloid precursor protein and amyloid-beta immunoreactivity in DBA/2J glaucomatous mouse retinas. Invest. Ophthalmol. Vis. Sci. 48: 5085-5090, 2007.
170. Yamamoto, R., Yoneda, S., and Hara, H. Neuroprotective effects of beta-secretase inhibitors against rat retinal ganglion cell death. Neurosci. Lett. 370:61-64, 2004.
171. Guo, L., Salt, T.E., Luong, V., et al. Targeting amyloidbeta in glaucoma treatment. Proc. Natl. Acad. Sci. U S A. 104:13444-13449, 2007.
172. Bolmont, T., Bouwens, A., Pache, C., et al. Label-free imaging of cerebral beta-amyloidosis with extended-focus optical coherence microscopy. J. Neurosci. 32:14548-14556, 2012.
173. Iadecola, C., Zhang, F., Niwa, K., et al. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat. Neurosci. 2:157-161, 1999.
174. Resch, H., Garhofer, G., Fuchsjager-Mayrl, G., Hommer, A., and Schmetterer, L. Endothelial dysfunction in glaucoma. Acta Ophthalmol. 87:4-12, 2009.
175. Tezel, G. The role of glia, mitochondria, and the immune system in glaucoma. Invest. Ophthalmol. Vis. Sci. 50: 1001-1012, 2009.
176. Wax, M.B., and Tezel, G. Immunoregulation of retinal ganglion cell fate in glaucoma. Exp. Eye Res. 88:825-830, 2009.
177. Li, X., Qian, S.H., and Sun, X.H. [Protection of autoimmunity induced by copolymer-1 on optic nerve: experiment with rat glaucoma models]. Zhonghua Yi Xue Za Zhi. 88:2152-2154, 2008.
178. Reichelt, J., Joachim, S.C., Pfeiffer, N., and Grus, F.H. Analysis of autoantibodies against human retinal antigens in sera of patients with glaucoma and ocular hypertension. Curr. Eye Res. 33:253-261, 2008.
179. Tezel, G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog. Retin. Eye Res. 25:490-513, 2006.
180. Osborne, N.N., Alvarez, C.N., and Del Olmo Aguado, S. Targeting mitochondrial dysfunction as in aging and glaucoma. Drug Discov. Today, 2014.
181. Chew E.Y. Nutrition Effects on Ocular Diseases in the Aging Eye. Invest. Ophthalmol. Vis. Sci. 2013;54: ORSF42-ORSF47.
182. Osborne, N.N. Mitochondria: their role in ganglion cell death and survival in primary open angle glaucoma. Exp. Eye Res. 90:750-757, 2010.
183. Osborne, N.N., and del Olmo-Aguado, S. Maintenance of retinal ganglion cell mitochondrial functions as a neuroprotective strategy in glaucoma. Curr. Opin. Pharmacol. 13:16-22, 2013.
184. Yu, D.Y., Cringle, S.J., Balaratnasingam, C., Morgan, W.H., Yu, P.K., and Su, E.N. Retinal ganglion cells: energetics, compartmentation, axonal transport, cytoskeletons and vulnerability. Prog. Retin. Eye Res. 36:217-246, 2013.
185. Yang, X.J., Ge, J., and Zhuo, Y.H. Role of mitochondria in the pathogenesis and treatment of glaucoma. Chin. Med. J. (Engl). 126:4358-4365, 2013.
186. Chrysostomou, V., Rezania, F., Trounce, I.A., and Crowston, J.G. Oxidative stress and mitochondrial dysfunction in glaucoma. Curr. Opin. Pharmacol. 13:12-15, 2013.
187. Hernandez, M.R. The optic nerve head in glaucoma: role of astrocytes in tissue remodeling. Prog. Retin. Eye Res. 19:297-321, 2000.
188. Prasanna, G., Krishnamoorthy, R., and Yorio, T. Endothelin, astrocytes and glaucoma. Exp. Eye Res. 93:170-177, 2011.
189. Resch, H., Karl, K., Weigert, G., et al. Effect of dual endothelin receptor blockade on ocular blood flow in patients with glaucoma and healthy subjects. Invest. Ophthalmol. Vis. Sci. 50:358-363, 2009.
190. Kur, J., Newman, E.A., and Chan-Ling, T. Cellular and physiological mechanisms underlying blood flow regulation in the retina and choroid in health and disease. Prog. Retin. Eye Res. 31:377-406, 2012.
191. Newman, E.A. Functional hyperemia and mechanisms of neurovascular coupling in the retinal vasculature. J. Cereb. Blood Flow Metab. 33:1685-1695, 2013.
192. Attwell, D., Buchan, A.M., Charpak, S., Lauritzen, M., Macvicar, B.A., and Newman, E.A. Glial and neuronal control of brain blood flow. Nature. 468:232-243, 2010.
193. Garhofer, G., Zawinka, C., Resch, H., Huemer, K.H., Schmetterer, L., and Dorner, G.T. Response of retinal vessel diameters to flicker stimulation in patients with early open angle glaucoma. J. Glaucoma. 13:340-344, 2004.
194. Gugleta, K., Waldmann, N., Polunina, A., et al. Retinal neurovascular coupling in patients with glaucoma and ocular hypertension and its association with the level of glaucomatous damage. Graefes Arch. Clin. Exp. Ophthalmol. 251:1577-1585, 2013.
195. Ergorul, C., and Levin, L.A. Solving the lost in translation problem: improving the effectiveness of translational research. Curr. Opin. Pharmacol. 13:108-114, 2013.
196. Hood, D.C., and Kardon, R.H. A framework for comparing structural and functional measures of glaucomatous damage. Prog. Retin. Eye Res. 26:688-710, 2007.
197. Werkmeister, R.M., Cherecheanu, A.P., Garhofer, G., Schmidl, D., and Schmetterer, L. Imaging of retinal ganglion cells in glaucoma: pitfalls and challenges. Cell. Tissue Res. 353:261-268, 2013.